AZN vs INBX · P/E 28, $288.38B cap vs rev $1.3M
AstraZeneca PLC (AZN) versus Inhibrx Biosciences, Inc. (INBX) — a side-by-side from cached financials, not a winner call.
AstraZeneca PLC (AZN) is a drug manufacturers - general company listed on US.
Inhibrx Biosciences, Inc. (INBX) is a biotechnology company listed on US.
AZN does not have a complete income-statement cache yet.
Latest reported INBX revenue for 2025-12-31 was $1.3M. Net income was -$140.1M. Revenue was up 550.0% from 2024-12-31 to 2025-12-31. INBX currently screens at market cap $1.28B.
AZN currently screens at market cap $288.38B and trailing P/E 28.0. INBX currently screens at market cap $1.28B.
Not investment advice. Open the AZN and INBX stock pages for the full models.
Not investment advice.